Country
Clinical Trials in New Zealand
Studies with at least one site in New Zealand. Open a trial for its sites in New Zealand, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 388Ganglioneuroblastoma, Nodular, Neuroblastoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for…
- Trial name
- NCT06172296
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 180 sites in United States, Australia and 3 more
- Volunteers
- 478 people
- Sponsor
- National Cancer Institute (NCI)
Bipolar Disorder Type I With Mania
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the…
- Trial name
- NCT06929273
- Testing
- KarXT, Lithium, Valproate
- Where
- 184 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 183 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor…
- Trial name
- INAVO121 (NCT05646862)
- Testing
- Inavolisib, Fulvestrant, Alpelisib
- Where
- 210 sites in United States, Argentina and 18 more
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary…
- Trial name
- NCT07284459
- Testing
- PIPE-791 Dose A, PIPE-791 Dose B
- Where
- 101 sites in Argentina, Australia and 14 more
- Volunteers
- 324 people
- Sponsor
- Contineum Therapeutics
Nodular BCC
Plasmonic PhotoThermal Therapy (PPTT) With Glucose-Coated Gold Nanoparticles (TSK-001) in Patients With Nodular Basal Cell Carcinoma (nBCC)
Investigational Device TSK-001 injectable glucose-functionalised gold nanoparticle solution for intratumoural administration (0.3 mg nanoparticles in 1mL water for injection) Laser device 808 nm Dose regimen TSK-001 Part 1…
- Trial name
- NCT07891949
- Testing
- TSK-001. Injectable solution of glucose-functionalised plasmonic gold nanoparticles (0.3 mg in 1 mL water for injection) for intratumoural administration., 808 nm near-infrared (NIR) diode laser (Hyper Diode 808)
- Where
- New Zealand
- Volunteers
- 78 people
- Sponsor
- Torskal SAS
Healthy Volunteers
A Study to Test a Single Dose of a New Tablet Formulation of TRTL-729
This study assesses the safety, tolerability, and pharmacokinetics (PK) of the tablet formulation of TRTL-729 in healthy adults.
- Trial name
- NCT07811063
- Testing
- TRTL-729
- Where
- New Zealand
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tortugas Neuroscience, Inc.
Completed, with results posted
All 990Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Mesothelioma, Pleural Mesothelioma
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the…
- Conditions
- Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Trial name
- DREAM3R (NCT04334759)
- Testing
- Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
- Where
- 57 sites in United States, Australia and 1 more
- Volunteers
- 214 people
- Sponsor
- PrECOG, LLC.
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.
- Trial name
- ARCHER (NCT04656561)
- Testing
- ANX007
- Where
- 53 sites in United States, Australia and 1 more
- Volunteers
- 270 people
- Sponsor
- Annexon, Inc.
Healthy, Obesity, Metabolically
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.
- Trial name
- NCT05378893
- Testing
- DR10624 for injection
- Where
- New Zealand
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie